CYP2C19, cytochrome P450 family 2 subfamily C member 19, 1557
N. diseases: 274; N. variants: 14
Source: ALL
| Disease | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year |
|---|---|---|---|---|---|---|---|
|
|
0.100 | GeneticVariation | disease | BEFREE | Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes of Helicobacter pylori isolates influence the outcome of triple therapy. | 30403784 | 2019 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Personalized therapy for Helicobacter pylori: CYP2C19 genotype effect on first-line triple therapy. | 30859680 | 2019 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Both clarithromycin-resistant Helicobacter pylori and CYP2C19 polymorphisms may be passed down for generations and are known risk factors for the failure of H. pylori eradication therapy. | 31264254 | 2019 |
|
|
0.100 | Biomarker | disease | BEFREE | Effect of Drug Combination on Omeprazole Metabolism by Cytochrome P450 2C19 in Helicobacter pylori Eradication Therapy. | 31366830 | 2019 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Simultaneous detection of human CYP2C19 polymorphisms and antibiotic resistance of Helicobacter pylori using a personalised diagnosis kit. | 29444465 | 2018 |
|
|
0.100 | GeneticVariation | disease | BEFREE | The present study aimed to assess the effects of CYP2C19 gene polymorphisms on proton pump inhibitor (PPI), amoxicillin, and levofloxacin triple therapy for Helicobacter pylori (Hp) eradication. | 28577017 | 2017 |
|
|
0.100 | Biomarker | disease | BEFREE | Influence of CYP2C19 on Helicobacter pylori eradication in Brazilian patients with functional dyspepsia. | 27706745 | 2016 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospective Randomized Study. | 27221874 | 2016 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole. | 27010145 | 2016 |
|
|
0.100 | GeneticVariation | disease | BEFREE | First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype. | 26730167 | 2015 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. | 24599773 | 2014 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Our aim was to investigate prophylaxis effects of famotidine, one of the representative histamine-2 receptor antagonists (H2RA), on gastric mucosal injury induced by dual therapy with low-dose aspirin and clopidogrel in relation to Helicobacter pylori (H. pylori) infection and CYP2C19 genotypes. | 24615745 | 2014 |
|
|
0.100 | Biomarker | disease | BEFREE | The known factors that have contributed to the decline of Helicobacter pylori (H. pylori) eradication rate include antibiotic resistance, poor compliance, high gastric acidity, high bacterial load, and cytochrome P450 2C19 (CYP2C19) polymorphism. | 25473155 | 2014 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. | 24914361 | 2014 |
|
|
0.100 | GeneticVariation | disease | BEFREE | CYP2C19 metabolizer genotype and Helicobacter pylori status were examined. | 23800161 | 2013 |
|
|
0.100 | GeneticVariation | disease | BEFREE | The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/- pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments. | 22493986 | 2012 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication. | 21361732 | 2011 |
|
|
0.100 | GeneticVariation | disease | BEFREE | In this study, we examined the usefulness of the prediction of the pharmacotherapeutic efficacy using a newly developed analysis system for HP CAM resistance and CYP2C19 genotypes. | 21132257 | 2011 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Fifteen Helicobacter pylori-negative volunteers with different CYP2C19 genotypes were randomly administered aspirin 100 mg, aspirin plus famotidine 20 mg twice daily, or aspirin plus lansoprazole 15 mg once daily for 7 days each in a crossover fashion. | 20663999 | 2011 |
|
|
0.100 | GeneticVariation | disease | BEFREE | CYP2C19*2, *3, *4, *5 and *17 genotypes were determined in healthy Helicobacter pylori-negative Caucasian subjects. | 19785625 | 2010 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Correlation of CYP2C19 genetic polymorphisms with helicobacter pylori eradication in patients with cirrhosis and peptic ulcer. | 20457439 | 2010 |
|
|
0.100 | GeneticVariation | disease | BEFREE | We determined the incidence of cytochrome P450 2C19 genotypes and the effect of cytochrome P450 2C19 genotypes on Helicobacter pylori eradication rates in 105 patients with Helicobacter pylori-positive chronic gastritis. | 20533108 | 2010 |
|
|
0.100 | GeneticVariation | disease | BEFREE | But no study correlated CYP2C19 genetic polymorphism with eradication of Helicobacter pylori in north Indian gastritis patients positive for H. pylori and hence this study. | 19942749 | 2009 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori. | 19552744 | 2009 |
|
|
0.100 | GeneticVariation | disease | BEFREE | We investigated whether the CYP2C19 genotype plays a role in the eradication rate of Helicobacter pylori (H. pylori) infection in patients receiving pantoprazole- or esomeprazole-based triple therapy. | 18637061 | 2008 |